# Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

> **NCT06663111** · — · RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **OTHER:** Blood samples for PK
- **OTHER:** Blood samples for PK

## Key facts

- **NCT ID:** NCT06663111
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-15
- **Primary completion:** 2025-12
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663111, "Rituximab and Ocrelizumab in Serum With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06663111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*